BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 32125093)

  • 1. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
    Mandarano M; Orecchini E; Bellezza G; Vannucci J; Ludovini V; Baglivo S; Tofanetti FR; Chiari R; Loreti E; Puma F; Sidoni A; Belladonna ML
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis.
    Wu D; Chen M; Chen S; Zhang S; Chen Y; Zhao Q; Xue K; Xue F; Chen X; Zhou M; Li H; Zheng J; Le Y; Cao H
    Clin Rheumatol; 2022 Oct; 41(10):3107-3117. PubMed ID: 35778590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1.
    Botticelli A; Mezi S; Pomati G; Cerbelli B; Cerbelli E; Roberto M; Giusti R; Cortellini A; Lionetto L; Scagnoli S; Zizzari IG; Nuti M; Simmaco M; Marchetti P
    Front Immunol; 2020; 11():1243. PubMed ID: 32733441
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma.
    Meireson A; Ferdinande L; Haspeslagh M; Hennart B; Allorge D; Ost P; Sundahl N; Spaas M; Demeyer A; Brochez L
    Front Immunol; 2021; 12():736498. PubMed ID: 34557196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer.
    Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Ann Surg; 2019 Jun; 269(6):1101-1108. PubMed ID: 31082908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
    Mitra D; Horick NK; Brackett DG; Mouw KW; Hornick JL; Ferrone S; Hong TS; Mamon H; Clark JW; Parikh AR; Allen JN; Ryan DP; Ting DT; Deshpande V; Wo JY
    Oncologist; 2019 Jun; 24(6):e275-e283. PubMed ID: 30755500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
    Mandarano M; Bellezza G; Belladonna ML; Vannucci J; Gili A; Ferri I; Lupi C; Ludovini V; Falabella G; Metro G; Mondanelli G; Chiari R; Cagini L; Stracci F; Roila F; Puma F; Volpi C; Sidoni A
    Front Immunol; 2020; 11():839. PubMed ID: 32536910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.
    de Jong RA; Nijman HW; Boezen HM; Volmer M; Ten Hoor KA; Krijnen J; van der Zee AG; Hollema H; Kema IP
    Int J Gynecol Cancer; 2011 Oct; 21(7):1320-7. PubMed ID: 21720257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of tryptophan catabolism in Hodgkin lymphoma.
    Masaki A; Ishida T; Maeda Y; Ito A; Suzuki S; Narita T; Kinoshita S; Takino H; Yoshida T; Ri M; Kusumoto S; Komatsu H; Inagaki H; Ueda R; Choi I; Suehiro Y; Iida S
    Cancer Sci; 2018 Jan; 109(1):74-83. PubMed ID: 29080383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
    Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
    Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
    Ma WJ; Wang X; Yan WT; Zhou ZG; Pan ZZ; Chen G; Zhang RX
    World J Gastroenterol; 2018 May; 24(20):2181-2190. PubMed ID: 29853736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.
    De Bacco MW; Carvalhal GF; MacGregor B; Marçal JMB; Wagner MB; Sonpavde GP; Fay AP
    Clin Genitourin Cancer; 2020 Jun; 18(3):e254-e259. PubMed ID: 32139302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
    Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
    Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.
    Wu L; Wang D; Chen Y; Qian M; Xu X; Zhang T; Bi N; Wang L
    Front Immunol; 2022; 13():906815. PubMed ID: 36032151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
    Ottenhof SR; Djajadiningrat RS; Thygesen HH; Jakobs PJ; Jóźwiak K; Heeren AM; de Jong J; Sanders J; Horenblas S; Jordanova ES
    Front Immunol; 2018; 9():1253. PubMed ID: 29942303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
    Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
    Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
    Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
    Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.